Processing of the Control Regime of Medicines for Pharmacotherapy of Chronic Pain Syndrome in the Field of Palliative Aid

Abstract

In the world from 10 to 55% people suffer from chronic pain syndrome. Therefore, timely reduction of pain helps to improve the quality of their life in all areas of activity. To improve the organizational and legal procedure for providing patients with drugs as part of palliative care, a control regime for non-steroidal anti-inflammatory drugs, non-narcotic and narcotic (opioid) analgesics and adjuvant (auxiliary) drugs, which prescribed by doctors for chronic pain syndrome was developed. The research materials were the current regulatory, legislative and instructive documents; statistics of the Ministry of Healthcare of Ukraine; instructions for medical use of medicines, websites of the Verkhovna Rada of Ukraine, the Ministry of Healthcare of Ukraine, the State Expert Center of the Ministry of Healthcare of Ukraine and others. We used documentary, comparative, systemic and regulatory methods of analysis. In the article, based on the analysis of the normative base, analyzed the medical and technological documents concerning the pharmacotherapy of chronic pain syndrome, allocated three classes of medicines. Processed the control regime of non-steroidal medicines, non-narcotic analgesics, narcotic (opioid) analgesics and adjuvant (auxiliary) drugs prescribed by doctors for chronic pain syndrome. Analyzed the normative and legal documents on the procedure for the circulation of narcotic, psychotropic and potent medicines in medical and pharmaceutical healthcare institutions in accordance with the licensed conditions for the conduct of economic activity. Established that the circulation of medicines for pharmacotherapy of chronic pain syndrome within palliative care in medical institutions carried out based on a license for medical practice, and in pharmacy institutions – based on a license for wholesale and retail trade of medicines.

Organization of the Pharmaceutical Business, Drug Technology and Forensic Pharmacy: Modern Trends in The Development of the Science of Pharmaceutical Law During the Covid-19 Pandemic

“…In the conditions of the pandemic of the coronavirus disease and the infectious spread of monkeypox [22,23], the issues of correct interpretation of the terminological apparatus and the addition of the necessary terms to the legislation (for example, pharmacy, etc.) for further improvement of the rules of drug circulation remain relevant [24][25][26][27][28][29]. On the other hand, the optimization of the system of legal relations "doctorpatient-pharmacist-lawyer" as a component of the organizational-legal system of medical care for patients based on the principles of pharmaceutical law in accordance with international GxP standards is a guarantee of the exclusion of forensic pharmaceutical risks and doctor's mistakes, provision of high-quality, timely and safe medical and pharmaceutical care, as well as further improvement of the Law of Ukraine "On Medicinal Products" as a legal basis for reforming competences in the field of health care and the pharmaceutical industry [57].…”

The Latest Quantum and Medical, Quantum and Pharmaceutical Technologies in Countering the Criminal and Legal, Forensic and Pharmaceutical Risks of Circulation of Falsified Drugs

“…According to a forensic medical assessment, these are light, moderate or severe injuries), including fatalities (death). Modern challenges in the field of health care are the treatment of the most common diseases associated with the consequences of COVID-19: infectious, oncological, cardiovascular, psychoneurological, orphan endocrinological, addictive diseases, injuries due to traffic accidents, injuries received during hostilities [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. However, the state guarantees the provision of patients during their outpatient and inpatient treatment with high-quality, effective, safe and economically available drugs of clinical and pharmacological, classification and legal, nomenclature and legal groups [40][41][42][43][44][45][46][47][48][49][50][51][52].…”

Системи Якості У Фармації: Мультидисциплінарний Контекст Державної Фармакопеї України

“…Сучасні захворювання (COVID-19, вірус мавпячої віспи, ВІЛ/СНІД, серцево-судинні, психо-неврологічні, адиктивні, туберкульоз, онкологічні, коморбідні та інш.) [11][12][13][14][15][16][17][18][19], з якими зітнулися всі без винятку країни світу, вимагають від сфери охорони здоров'я і фармації нових схем фармакотерапії. Забезпечення пацієнтів ефективними, безпечними, доступними, якісними ЛЗ ґрунтується на системах контролю якості відповідно до вимог Державної Фармакопеї України (ДФУ).…”